Roche Mulls Xenical Rx-To-OTC Switch To Stop Slimming Prescription Sales
This article was originally published in The Tan Sheet
Executive Summary
Roche's slumping anti-obesity prescription drug sales and a vacuum of high-profile products in the over-the-counter drug and dietary supplement weight-loss markets could persuade the firm to pursue an Rx-to-OTC switch for Xenical